Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

BACKGROUND: Rituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both antibodies are delivered by the intravenous (IV) route, but recently subcutaneous (SC) formulations have been developed. Subcutaneous administration of mAbs can offer substantial...

Descripción completa

Detalles Bibliográficos
Autores principales: Shpilberg, O, Jackisch, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776971/
https://www.ncbi.nlm.nih.gov/pubmed/24002601
http://dx.doi.org/10.1038/bjc.2013.371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776971/
https://www.ncbi.nlm.nih.gov/pubmed/24002601
http://dx.doi.org/10.1038/bjc.2013.371

Ejemplares similares